Arch Therapeutics, Inc. (ARTH) financial statements (2022 and earlier)
Company profile
| Business Address |
235 WALNUT STREET, SUITE 6 FRAMINGHAM, MA 01702 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 1,088 | 959 | 2,180 | 4,667 | 5,994 | |||
| Cash and cash equivalents | 1,088 | 959 | 2,180 | 4,667 | 5,994 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,093 | 968 | 347 | |||||
| Inventory | 1,093 | 968 | 347 | |||||
| Prepaid expense | 152 | |||||||
| Other undisclosed current assets | 354 | 216 | 363 | 85 | ||||
| Total current assets: | 2,536 | 2,143 | 2,890 | 4,819 | 6,079 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 4 | 5 | 9 | 17 | 7 | |||
| Other noncurrent assets | 4 | 4 | 4 | 4 | 4 | |||
| Total noncurrent assets: | 8 | 8 | 13 | 21 | 11 | |||
| TOTAL ASSETS: | 2,544 | 2,151 | 2,902 | 4,840 | 6,090 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 749 | 342 | 534 | 161 | 265 | |||
| Accounts payable | 749 | 342 | 534 | 161 | 265 | |||
| Debt | 37 | |||||||
| Derivative instruments and hedges, liabilities | 1,000 | |||||||
| Other undisclosed current liabilities | 204 | 267 | 180 | 127 | 169 | |||
| Total current liabilities: | 1,952 | 646 | 714 | 288 | 434 | |||
| Noncurrent Liabilities | ||||||||
| Liabilities, other than long-term debt | 1,207 | 2,316 | 2,996 | 3,192 | 3,430 | |||
| Derivative instruments and hedges, liabilities | 1,207 | 2,316 | 2,996 | 3,192 | 3,430 | |||
| Other undisclosed noncurrent liabilities | 1,807 | 689 | ||||||
| Total noncurrent liabilities: | 3,015 | 3,005 | 2,996 | 3,192 | 3,430 | |||
| Total liabilities: | 4,967 | 3,652 | 3,710 | 3,480 | 3,864 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | (2,424) | (1,500) | (807) | 1,360 | 2,227 | |||
| Common stock | 237 | 193 | 173 | 160 | 150 | |||
| Additional paid in capital | 48,687 | 41,863 | 37,885 | 35,517 | 31,580 | |||
| Accumulated deficit | (51,347) | (43,556) | (38,865) | (34,317) | (29,503) | |||
| Total stockholders' equity: | (2,424) | (1,500) | (807) | 1,360 | 2,227 | |||
| TOTAL LIABILITIES AND EQUITY: | 2,544 | 2,151 | 2,902 | 4,840 | 6,090 | |||
Income statement (P&L) ($ in thousands)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | (4) | ||||||
| Cost of revenue (Other undisclosed Cost of revenue) | (33) | ||||||
| Gross profit: | (27) | ||||||
| Operating expenses | (4,876) | (5,371) | (6,372) | (7,450) | (7,303) | ||
| Operating loss: | (4,903) | (5,371) | (6,372) | (7,450) | (7,303) | ||
| Nonoperating expense (Other undisclosed Nonoperating expense) | (40) | ||||||
| Interest and debt expense | (121) | (131) | |||||
| Loss before gain (loss) on sale of properties: | (5,064) | (5,371) | (6,372) | (7,450) | (7,434) | ||
| Other undisclosed net income | 178 | 679 | |||||
| Net loss: | (4,886) | (4,691) | (6,372) | (7,450) | (7,434) | ||
| Other undisclosed net income (loss) attributable to parent | 40 | 1,824 | 2,636 | (355) | |||
| Net loss available to common stockholders, diluted: | (4,845) | (4,691) | (4,548) | (4,814) | (7,789) | ||
Comprehensive Income ($ in thousands)
| 12/31/2021 TTM | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (4,886) | (4,691) | (6,372) | (7,450) | (7,434) | ||
| Comprehensive loss, net of tax, attributable to parent: | (4,886) | (4,691) | (6,372) | (7,450) | (7,434) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.